Liu JF - Search Results

1

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Konstantinopoulos PA, Cheng SC, Lee EK, da Costa AABA, Gulhan D, Wahner Hendrickson AE, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Penson RT, Stover EH, Curtis J, Sawyer H, Polak M, Chowdhury D, D'Andrea AD, Färkkilä A, Shapiro GI, Matulonis UA. Konstantinopoulos PA, et al. Among authors: liu jf. JCO Precis Oncol. 2024 Apr;8:e2300635. doi: 10.1200/PO.23.00635. JCO Precis Oncol. 2024. PMID: 38635934 Free PMC article. Clinical Trial.

2

Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.

Liu J, Matulonis U. Liu J, et al. J Natl Compr Canc Netw. 2006 Oct;4(9):947-53. doi: 10.6004/jnccn.2006.0078. J Natl Compr Canc Netw. 2006. PMID: 17020671 Review.

3

Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.

Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Callahan MJ, et al. Clin Cancer Res. 2008 Dec 1;14(23):7667-73. doi: 10.1158/1078-0432.CCR-08-0479. Clin Cancer Res. 2008. PMID: 19047092 Free PMC article.

4

Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.

Liu JF, Hirsch MS, Lee H, Matulonis UA. Liu JF, et al. Gynecol Oncol. 2009 Dec;115(3):401-6. doi: 10.1016/j.ygyno.2009.08.023. Epub 2009 Sep 30. Gynecol Oncol. 2009. PMID: 19796795

5

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Clauss A, et al. Neoplasia. 2010 Feb;12(2):161-72. doi: 10.1593/neo.91542. Neoplasia. 2010. PMID: 20126474 Free PMC article.

6

New advances in ovarian cancer.

Liu J, Matulonis UA. Liu J, et al. Oncology (Williston Park). 2010 Jul;24(8):721-8. Oncology (Williston Park). 2010. PMID: 20718251 Free article. Review.

7

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC. Matulonis UA, et al. PLoS One. 2011;6(9):e24433. doi: 10.1371/journal.pone.0024433. Epub 2011 Sep 8. PLoS One. 2011. PMID: 21931712 Free PMC article.

8

Anti-angiogenic agents in ovarian cancer: dawn of a new era?

Liu J, Matulonis UA. Liu J, et al. Curr Oncol Rep. 2011 Dec;13(6):450-8. doi: 10.1007/s11912-011-0194-8. Curr Oncol Rep. 2011. PMID: 21993845 Review.

9

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA. Bentink S, et al. PLoS One. 2012;7(2):e30269. doi: 10.1371/journal.pone.0030269. Epub 2012 Feb 13. PLoS One. 2012. PMID: 22348002 Free PMC article.

10

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN. Liu J, et al. Cancer Genet. 2012 Jan-Feb;205(1-2):34-41. doi: 10.1016/j.cancergen.2012.01.008. Cancer Genet. 2012. PMID: 22429596 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,632 results

Search Page